SynOx Therapeutics raised an additional funding in a Series B extension led by Gilde Healthcare, bringing total capital to $92 million to support the Phase 3 TANGENT trial of emactuzumab.

Oct 30, 2024•about 1 year ago

Amount Raised

$92 Million

Round Type

series b

DublinTherapeuticsBiotechnologyHealth Care

Investors

Bioqube VenturesHealth CapForbionGilde Healthcare

Description

SynOx Therapeutics Limited has announced the final close of its Series B financing, now totaling $92 million. The funding will support a registrational Phase 3 clinical trial for emactuzumab, targeting Tenosynovial Giant Cell Tumour.

Company Information

Company

SynOx Therapeutics

Location

Dublin, Dublin, Ireland

About

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

Related People

4 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends